Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $20,258 | 5 | 62.8% |
| Unspecified | $7,289 | 11 | 22.6% |
| Honoraria | $4,070 | 1 | 12.6% |
| Food and Beverage | $471.56 | 4 | 1.5% |
| Travel and Lodging | $159.99 | 1 | 0.5% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $20,078 | 4 | $0 (2020) |
| AbbVie, Inc. | $10,125 | 12 | $0 (2019) |
| RECORDATI_RARE_DISEASES_INC. | $1,622 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $284.98 | 2 | $0 (2018) |
| Alexion Pharmaceuticals, Inc. | $139.74 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,761 | 4 | RECORDATI_RARE_DISEASES_INC. ($1,622) |
| 2020 | $4,070 | 1 | PFIZER INC. ($4,070) |
| 2019 | $6,238 | 8 | PFIZER INC. ($5,320) |
| 2018 | $7,598 | 4 | PFIZER INC. ($5,313) |
| 2017 | $12,582 | 5 | AbbVie, Inc. ($7,207) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $139.74 | General |
| Category: Rare Disease | ||||||
| 03/22/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $248.50 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 01/03/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $623.00 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 10/09/2020 | PFIZER INC. | SOMAVERT (Drug) | Honoraria | Cash or cash equivalent | $4,070.00 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 08/14/2019 | PFIZER INC. | ELIQUIS (Drug) | Consulting Fee | Cash or cash equivalent | $5,320.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $457.60 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $58.57 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $36.06 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $18.86 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/05/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $18.75 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/04/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $204.06 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 04/04/2019 | AbbVie, Inc. | Androgel (Drug) | — | In-kind items and services | $124.07 | Research |
| Study: M16-100 • Category: Endocrinology | ||||||
| 09/27/2018 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $5,313.00 | General |
| 03/16/2018 | Novartis Pharmaceuticals Corporation | LCI699 (Drug) | Travel and Lodging | In-kind items and services | $159.99 | General |
| 03/16/2018 | Novartis Pharmaceuticals Corporation | LCI699 (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| 01/03/2018 | AbbVie, Inc. | Androgel (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Endocrinology | ||||||
| 12/15/2017 | PFIZER INC. | SOMAVERT (Drug) | Consulting Fee | Cash or cash equivalent | $5,375.20 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 08/28/2017 | AbbVie, Inc. | Androgel (Drug) | — | Cash or cash equivalent | $4,750.00 | Research |
| Category: Endocrinology | ||||||
| 04/01/2017 | AbbVie, Inc. | Androgel (Drug) | Food and Beverage | In-kind items and services | $114.39 | General |
| Category: Endocrinology | ||||||
| 03/31/2017 | AbbVie, Inc. | Androgel (Drug) | Food and Beverage | In-kind items and services | $92.44 | General |
| Category: Endocrinology | ||||||
| 03/14/2017 | AbbVie, Inc. | Androgel (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LCI699-RECAG-PASS-0572 | RECORDATI_RARE_DISEASES_INC. | $1,622 | 3 |
| M16-100 | AbbVie, Inc. | $917.97 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 132 | 177 | $38,180 | $15,798 |
| 2022 | 2 | 123 | 157 | $26,430 | $13,348 |
| 2021 | 2 | 123 | 151 | $27,700 | $14,632 |
| 2020 | 4 | 136 | 143 | $24,568 | $8,696 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 57 | 84 | $22,680 | $9,179 | 40.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 75 | 93 | $15,500 | $6,618 | 42.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 103 | $14,550 | $7,556 | 51.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 44 | 54 | $11,880 | $5,792 | 48.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 62 | 82 | $18,040 | $9,202 | 51.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 61 | 69 | $9,660 | $5,429 | 56.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 58 | 65 | $9,100 | $4,142 | 45.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 27 | 27 | $5,940 | $1,732 | 29.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 15 | $3,910 | $1,175 | 30.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 21 | 21 | $1,953 | $936.13 | 47.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 15 | 15 | $3,665 | $710.78 | 19.4% |
About Dr. Peter Snyder, MD
Dr. Peter Snyder, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255361333.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Snyder, MD has received a total of $32,249 in payments from pharmaceutical and medical device companies, with $1,761 received in 2024. These payments were reported across 22 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($20,258).
As a Medicare-enrolled provider, Snyder has provided services to 514 Medicare beneficiaries, totaling 628 services with total Medicare billing of $52,473. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Philadelphia, PA
- Active Since 07/04/2006
- Last Updated 04/24/2013
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1255361333
Products in Payments
- Androgel (Drug) $10,125
- SOMAVERT (Drug) $9,445
- ELIQUIS (Drug) $5,320
- OSILODROSTAT (Drug) $1,622
- LCI699 (Drug) $284.98
- STRENSIQ (Biological) $139.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Philadelphia
Dr. Serge Jabbour, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.7M
Jane Mayrin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $928,176
Mitchell Lazar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $432,095
Jeffrey Freeman, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $403,058
Dr. Monika Shirodkar, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $59,532
Mihaela Biscoveanu, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $58,973